OOIR: Observatory of International Research

Papers

(The H4-Index of Thorax is 37. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Vaping and CBD: can new technology overcome old problems?	142
Case-based discussion: neonates on extracorporeal membrane oxygenation for undiagnosed recalcitrant pulmonary hypertension—management challenges	127
E-cigarette use in young adults and adolescents: not so safe?	124
Journal club	124
Fibrosing mediastinitis: ‘haemoptysis in the Heartland’	117
Strengthening the evidence base to support stronger regulation of social media based advertising of e-cigarette products to youth	97
Beware, vaping e-cigarettes around children is adversely impacting their lung health	89
Ablation for lung cancer: hot or cold intervention	73
Neuropsychiatric diagnoses after montelukast initiation in paediatric patients with asthma	73
Lung development genes, adult lung function and cardiovascular comorbidities	68
Correction:British Thoracic Society Winter Meeting 2023	68
Rectal organoid morphometric analysis (ROMA)—re: optimising measurements automatically	68
Complex coexistence of COPD and cardiovascular disease	67
Emulated trial investigating effects of multiple treatments: estimating combined effects of mucoactive nebulisers in cystic fibrosis using registry data	65
TB PCR in BAL and EBUS-TBNA samples for the diagnosis of pulmonary and mediastinal lymph node TB: retrospective TRiBE study	62
British Thoracic Society Guideline for pleural disease	56
Automatic oxygen titration versus constant oxygen flow rates during walking in COPD: a randomised controlled, double-blind, crossover trial	56
Ambient heat exposure and COPD hospitalisations in England: a nationwide case-crossover study during 2007–2018	51
Ultra-low-dose CT versus chest X-ray for patients suspected of pulmonary disease at the emergency department: a multicentre randomised clinical trial	50
Highlights from this issue	49
Correction:RAGE-induced ILC2 expansion in acute lung injury due to haemorrhagic shock	49
Association between vitamin D status at 3 years and eosinophilic asthma in 6-year-old children with a history of severe bronchiolitis	48
Muscle memory: genetic factors underlying functional impairment in COPD	47
Short-term exposure to ultrafine particles and asthma hospital admissions in children in Copenhagen, Denmark	46
Ageing and ivacaftor: unravelling the long-term effects	46

Airflow obstruction, impaired lung function and risk of sudden cardiac death: a prospective cohort study	45
BTS Clinical Statement on air travel for passengers with respiratory disease	45
Lower airway microbiota in COPD and healthy controls	44
Implications of the 2022 lung function update and GLI global reference equations among patients with interstitial lung disease	42
Differentiation of malignant from benign pleural effusions based on artificial intelligence	42
Prevalence of lung cysts in adolescents and adults with a germlineDICER1pathogenic/likely pathogenic variant: a report from the National Institutes of Health and International Pleuropulmonary B	40
Paediatric asthma hospitalisations continue to decrease in Finland and Sweden between 2015 and 2020	39
Toxic metals and lung health: silent poisons?	39
Lung function as independent predictor of cardiovascular disease risk: implications for practice and policy	39
Activation of epithelial and inflammatory pathways in adolescent elite athletes exposed to intense exercise and air pollution	38
Impact of sex on severe asthma: a cross-sectional retrospective analysis of UK primary and specialist care	37
COPD in Africa: risk factors, hospitalisation, readmission and associated outcomes—a systematic review and meta-analysis	37
Intensive care unit interventions to promote sleep and circadian biology in reducing incident delirium: a scoping review	37
Greenhouse gas emissions associated with suboptimal asthma care in the UK: the SABINA healthCARe-Based envirONmental cost of treatment (CARBON) study	37